Coblopasvir and sofosbuvir for treatment of chronic hepatitis C virus infection in China: A single‐arm, open‐label, phase 3 trial

BACKGROUND & AIM: An affordable, pangenotypic regimen remains as an unmet medical need for chronic hepatitis C patients in China. This single‐arm, open‐label, multicenter, phase 3 trial evaluated the efficacy and safety of coblopasvir, a pangenotypic non‐structural protein 5A (NS5A) inhibitor, c...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Yanhang, Kong, Fei, Li, Guangming, Li, Cheng, Zheng, Sujun, Lin, Jianmei, Wen, Xiaofeng, Hu, Jinghua, Wang, Xiaozhong, Wu, Xiaofeng, Xing, Huichun, Jia, Jidong, Jia, Zhansheng, Guan, Yujuan, Li, Chenghao, Wu, Guicheng, Gao, Zhiliang, Mou, Zhuangbo, Ning, Qin, Mao, Qing, Yang, Yongfeng, Ning, Jing, Li, Li, Pan, Hai, Zhou, Desheng, Ding, Yanhua, Qin, Hong, Niu, Junqi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Viral Hepatitis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7702130/
https://www.ncbi.nlm.nih.gov/pubmed/33047868
http://dx.doi.org/10.1111/liv.14633

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7702130/
https://www.ncbi.nlm.nih.gov/pubmed/33047868
http://dx.doi.org/10.1111/liv.14633

Ejemplares similares